0001493152-22-004799.txt : 20220216 0001493152-22-004799.hdr.sgml : 20220216 20220216171548 ACCESSION NUMBER: 0001493152-22-004799 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220214 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220216 DATE AS OF CHANGE: 20220216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40761 FILM NUMBER: 22644651 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8-k.htm
0001630113 false 0001630113 2022-02-14 2022-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): February 14, 2022

 

BIOTRICITY INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada   000-56074   30-0983531
(State or Other Jurisdiction of
Incorporation or Organization)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

203 Redwood Parkway, Suite 600
Redwood City, California 94065

 

(Address of Principal Executive Offices)

 

(650) 832-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BTCY   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


 

 

 

Item 2.02 Results of Operations and Financial Condition

 

On February 14, 2022, Biotricity, Inc. (the “Company”) issued a press release reporting certain unaudited financial results for the fiscal quarter ended December 31, 2022. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall any of them be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits. The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K:

 

Exhibit Number   Description
99.1   Press Release dated February 14, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: February 16, 2022

 

  BIOTRICITY INC.
     
  By: /s/ John Ayanoglou
   

John Ayanoglou

    Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Biotricity Releases Fiscal 2022 Third Quarter Financial Results

 

Management to host investor call on Tuesday February 15th at 4:15 pm ET

 

  ● 93% YOY Revenue Gains to $1.93 Million
  ● Revenue Outpaces SG&A Increase by 2.2x
  ● Cash Position of $16.8 Million at Quarter End Is Highest Ever
  ● Continues to Anticipate Full-Year Triple-Digit Revenue Growth

 

REDWOOD CITY, CA / ACCESSWIRE / February 14, 2022 / Biotricity, Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year’s third quarter ended December 31, 2021.

 

Q3-FY22 financial and operating highlights include:

 

  ● Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- million reported in Q2FY22.
  ● Scaling well - SG&A rose just 40%, R&D up 32%, compared with 93% revenue increase.
  ● Net loss of $7.34 million or $0.15 per share, impacted by one-time derivative fair value and accretion expenses of $1.34 million during the quarter; excluding these non-recurring items would result in an adjusted net loss of $6.0 million or $0.12 per share.

 

“The December quarter was pivotal for our company, said Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity. “We were still able to generate modest sequential growth despite the challenges of omnicron, clinical closures, and reduced scheduling and staffing.

 

“We also had several game-changing product introductions, as well as the foundational FDA clearance of Biotres, which has greatly expanded our total addressable cardiac market and has positioned us well to make 2022 an inflectional year. Our recently completed $12 million debt financing has firmly positioned us to aggressively pursue our expansion plans and solidify our sector tech leadership.”

 

As important, last quarter the Company brought to market Bioheart, a heart monitor now directly available to consumers. The device offers the same continuous heart monitoring technology used by physicians. It allows patients to manage heart conditions with retrospective snapshots and long-term data collection. A first of its kind feature that is not possible through traditional solutions that require manual data collection and can only record up to a few minutes. It opens a new market and revenue stream for Biotricity and has expanded the company’s total addressable heart monitoring market by $1.24 billion. Bioheart can be purchased at www.bioheart.com and now on Amazon for $199.

 

“The addition of Bioheart is groundbreaking and marks an important step in achieving our ultimate goal of building a complete cardiac ecosystem to service individuals with heart health issues. I am proud to note that Bioheart was brought to market in less than a year, ahead of schedule,” Dr. Al-Siddiq added.

 

Additionally, in December the Company successfully completed a $12 million non-dilutive debt financing on favorable terms. Intended use of proceeds was to extinguish $1.6 million in less favorable legacy debt, support the Company’s inventory build, and finance annul recurring revenue subscriptions.

 

 

 

 

Looking ahead, the Company noted it plans to recapture any sales temporarily lost to covid in CY2021, as cardiac disease is not retreating but rather made people more aware of its risks as a co-morbidity. Biotricity is expanding its geographic footprint as it strategically adds top-tier cardiac medical salespeople, who then increase the number of cardiac centers participating in its Biotricity ecosystem. Its end goal is to collapse cardiac services within clinics and hospitals into one ecosystem - so that doctors are using the cloud-based Biotricity ecosystem not merely to deliver diagnostics, but diagnostics, disease management, remote management, and telemedicine integrated seamlessly all in one place.

 

“With our busy new product launch and services schedule for calendar 2022, ours is a classic case of the whole being far more valuable than the sum of its parts. Cardiac disease progression is rarely reversed, and we expect to accompany every new patient throughout their lifelong cardiac health journey with a growing spectrum of remote monitoring solutions featuring advanced AI technology,” Dr. Waqaas concluded. “Transforming the state of cardiac health is the reason I founded Biotricity.”

 

As part of its commitment to communicate proactively with shareholders, in December, Dr. Al-Siddiq published a comprehensive shareholder letter including milestones, a products roadmap, growth strategy, and 2022 goals. It discussed the recently FDA cleared Biotres, and the competitive advantages of a three lead device for ECG and arrhythmia monitoring intended for lower risk patients. Biotres opens a new market and increases the Company’s total addressable market from $1 billion to $5.7 billion. The device is slated to be widely available starting April 1. The Letter can be seen here: Biotricity Shareholder Letter

 

Full details of the Company’s financial results will be filed with the SEC on Form 10-Q and published this week on www.sec.gov.

 

Management Call

 

Company management will be hosting a call on Tuesday, February 15, 2022 at 4:15pm ET. A live webcast of the conference call can be accessed by clicking on the following link: https://pr.report/a73-wUZW. A full replay of the presentation will be available at the same link shortly after the conclusion of the live presentation.

 

The live and archived webcast of the conference call will also be accessible on the Investor Relations section of the company’s website at www.biotricity.com. The phone replay will be available approximately two hours following the end of the call, and will remain available for one week. To access the call replay dial-in information, please Click Here and enter replay passcode: 6231038.

 

About Biotricity Inc.

 

Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit

 

www.biotricity.com.

 

 

 

 

Important Cautions Regarding Forward-Looking Statements

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

Use of Non-GAAP Information

 

In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company’s internal reporting to evaluate its operations and the performance of senior management.

 

Contacts:

 

Investor Relations:

Biotricity Inc.

1-800-590-4155

investors@biotricity.com

 

SOURCE: Biotricity Inc.

 

 

 

 EX-101.SCH 3 btcy-20220214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 btcy-20220214_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 btcy-20220214_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 14, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2022
Entity File Number 000-56074
Entity Registrant Name BIOTRICITY INC.
Entity Central Index Key 0001630113
Entity Tax Identification Number 30-0983531
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 203 Redwood Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 832-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol BTCY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001630113 2022-02-14 2022-02-14 iso4217:USD shares iso4217:USD shares 0001630113 false 8-K 2022-02-14 BIOTRICITY INC. NV 000-56074 30-0983531 203 Redwood Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 false false false false Common Stock, par value $0.001 per share BTCY NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm btcy-20220214.xsd btcy-20220214_lab.xml btcy-20220214_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "btcy-20220214_lab.xml" ] }, "presentationLink": { "local": [ "btcy-20220214_pre.xml" ] }, "schema": { "local": [ "btcy-20220214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20220214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-14to2022-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biotricity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-02-14to2022-02-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-004799-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-004799-xbrl.zip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end